研究单位:[1]Geneplus-Beijing Co. Ltd.[2]Xuanwu Hospital Capital Medical University Beijing,Beijing,China,100053[3]Beijing hospital Beijing,Beijing,China,100730[4]Institute of Hepatopancreatobiliary Surgery,Chongqing General Hospital,University of Chinese Academy of Sciences (UCAS) Chongqing,Chongqing,China,401147[5]Tongji Hospital affiliated to Tongji Medical College of Huazhong University Wuhan,Hubei,China,430030[6]Eastern Hepatobiliary Surgery Hospital,Second Military Medical University Shanghai,Shanghai,China,200438
研究目的:
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors